GlassScriptPhysician profile
Robert Henry Blackwell
NPI 1346569480
$4,797.10
in general payments reported to CMS, 2019-2025
27 companies · $602 in 2025
The $602 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $128 · 2021: $808 · 2022: $1,130 · 2023: $1,121 · 2024: $546 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901 · Entertainment: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.51 |
| Entertainment | $368.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Southern Implants North America INC | $1,661.65 | 2020-2023 | |
| Cook Medical LLC | $615.73 | 2019-2024 | Litho 150, Resonance, Fiber Dust |
| Olympus America INC. | $402.11 | 2019-2023 | Itind System, Soltive |
| Keystone Dental INC. | $368.99 | 2025 | |
| Janssen Biotech, INC. | $291.17 | 2019-2025 | Erleada, Imbruvica, Darzalex |
| Boston Scientific Corporation | $285.29 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $248.67 | 2021-2025 | Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $200.60 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $91.43 | 2019-2025 | Xtandi |
| Abbvie INC. | $81.11 | 2024-2025 | |
| Daiichi Sankyo INC. | $65.31 | 2022-2025 | Datroway, Enhertu |
| Eisai INC. | $64.37 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $61.63 | 2022-2025 | |
| Lilly USA, LLC | $54.85 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Pfizer INC. | $50.14 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $47.25 | 2022 | |
| Genzyme Corporation | $43.01 | 2021-2022 | |
| Amgen INC. | $28.28 | 2022 | |
| Exelixis INC. | $21.07 | 2024 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $17.03 | 2022 | |
| Caris Mpi, INC. | $16.70 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $14.11 | 2023 | Krazati |
| Progenics Pharmaceuticals, INC. | $13.67 | 2023 | Pylarify |
| Emd Serono, INC. | $13.65 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.62 | 2021 | |
| Clovis Oncology, INC. | $12.98 | 2019 | |
| Isoray, INC | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Blackwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.